Taylor & Francis Group
Browse

File(s) not publicly available

Asthma Remission one, none and one-hundred thousand: the relevance of the patient’s view

Version 2 2024-06-25, 15:00
Version 1 2024-06-13, 19:00
online resource
posted on 2024-06-13, 19:00 authored by Matteo Bonini, Simona Barbaglia, Gianna Camiciottoli, Stefano Del Giacco, Fabiano Di Marco, Andrea Matucci, Claudio Micheletto, Alberto Papi, Patrizio Pasqualetti, Girolamo Pelaia, Fabio Luigi Massimo Ricciardolo, Paola Rogliani, Gianenrico Senna, Massimo Triggiani, Carlo Vancheri, Giorgio Walter Canonica

Achieving remission in severe asthma holds paramount importance in elevating patient quality of life and reducing both individual and societal burdens associated with this chronic condition. This study centres on identifying pivotal patient-relevant endpoints through standardized, reproducible methods, while also developing a patient-centric definition of remission, essential for effective disease management.

A discrete choice experiment (DCE) was conducted to assess patients’ perceptions on the four primary criteria for defining severe asthma remission, as outlined by the SANI survey. Additionally, it investigated the correlation between these perceptions and improvements in the doctor-patient therapeutic alliance during treatment decision-making.

249 patients (70% aged between 31-60, 59% women and 82% without other pathologies requiring corticosteroids) prioritize the use of oral corticosteroids (OCS, 48%) and the Asthma Control Test (ACT, 27%) in defining their condition, ranking these above lung function and exacerbations. This preference for OCS stems from its direct role in treatment, tangible tracking, immediate symptom relief, and being a concrete measure of disease severity compared to the less predictable and quantifiable exacerbations.

This study explores severe asthma remission from patients’ perspectives using clinician-evaluated parameters. The DCE revealed that most patients highly value OCS and the ACT, prefer moderate improvement, and avoid cortisone cycles. No definitive preference was found for lung function status. Integrating patient-reported information with professional insights is crucial for effective management and future research. Personalized treatment plans focusing on patient preferences, adherence, and alternative therapies aim to achieve remission and enhance quality of life.

Funding

This work was supported by AstraZeneca Italy.

History

Usage metrics

    Journal of Asthma

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC